In final draft guidance, the National Institute for Health and Care Excellence recommended atogepant. It’s the first of a new type of oral treatment option for preventing both chronic and episodic migraines. While initially positioned to be prescribed in secondary care, there is potential for atogepant to be monitored in primary care and for GPs to provide follow-up appointments.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
